Kairos Ventures

06/15/2024

Thrilled to share that Joshua Roth, former CTO of home security provider Ring, has joined PteroDynamics Inc.'s board of directors. Josh's extensive experience in scaling global tech operations and his hands-on expertise in hardware and software innovation will be invaluable as PteroDynamics advances its innovative Transwing® aircraft, addressing critical needs in both commercial and defense sectors.

Roth Brings Deep Operational Experience in Scaling Global Technology Operations and Building Platform Solutions COLORADO SPRINGS, COLORADO, USA, June 11, 2024 /EINPresswire.com/ -- PteroDynamics Inc., an innovator in autonomous vertical takeoff and landing (VTOL) aircraft systems, today announced th...

06/15/2024

Foldax Inc. announced positive 30-day results following surgery from their clinical study of the TRIA™ mitral surgical heart valve. The study in India demonstrated excellent safety and hemodynamics, with no signs of calcification or deterioration. TRIA valves, designed with the proprietary LifePolymer™, resist calcification and are robotically produced for maximum quality and precision. This innovation promises a durable heart valve solution without long-term anticoagulants, offering a transformative option for patients with mitral valve disease.

SALT LAKE CITY, June 11, 2024--Foldax reported positive 30-day data for the TRIA mitral surgical heart valve using LifePolymer, including favorable safety and hemodynamics.

06/13/2024

Excited to announce that a member of our portfolio, Actuate Therapeutics, Inc., plans to sell nearly 5.56 million shares at $8-$10 each in their upcoming IPO. Actuate expects to raise up to $52.4 million to support their mission to develop therapies for difficult-to-treat cancers. Actuate plans to list on the Nasdaq under the symbol ACTU.

https://www.marketwatch.com/amp/story/actuate-therapeutics-to-sell-5-56-million-shares-at-8-10-each-in-ipo-b5e05e8d

05/30/2024

Neuro-Bio Ltd., in collaboration with an international team of clinicians and neuroscientists, have published an insightful perspective which offers an alternative to the amyloid hypothesis in the etiology of Alzheimer's disease. Their review, published in Alzheimer's & Dementia, presents evidence of a pivotal molecule, T14, which could serve as a pre-symptomatic biomarker for neurodegeneration and inspire new therapeutic strategies for Alzheimer's disease.

An international team of clinicians and neuroscientists have published a new perspective on the process of neurodegeneration. Their findings review evidence for a mechanism upstream of amyloid including the key neurochemical driving this process.

05/29/2024

Thrilled to announce that a member of our portfolio, Actuate Therapeutics, Inc., has filed to raise up to $50M in an initial public offering.

Actuate Therapeutics is focused on developing therapies for the treatment of difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The company has exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago and Northwestern University. Its lead candidate, elraglusib (9-ING-41), is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, with top line results expected in the 1Q25.

Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering.

05/15/2024

An insightful article by Steven Leibson published in the Electronic Engineering Journal highlighting the exciting breakthrough in computing unveiled by MemVerge at Nvidia’s GTC conference in March.

The experiment conducted by MemVerge in collaboration with Micron Technology and Supermicro showcased a 2X improvement in system throughput using their innovative Memory Machine software layer, seamlessly integrating local DRAM, persistent memory, and Compute Express Link (CXL) memory pools. This advancement not only enhances performance but also optimizes cost structures and resource utilization in data centers, demonstrating how CXL introduces a third dimension in memory hierarchy with immense potential.

Dr. Emilio Lizardo/Lord John Whorfin: “May I pass along my congratulations for your great interdimensional breakthrough. I am sure, in the miserable annals of the Earth, you will be duly enshrined.…

05/08/2024

Vivodyne is pleased to announce the appointment of Julie O'Shaughnessy as its Chief Operating Officer. With her extensive leadership experience at Resilience and Amazon Web Services, Julie will drive operational excellence and strategic growth initiatives. Her expertise will be instrumental as Vivodyne continues to expand its team and scale its platform, advancing drug discovery through testing using their proprietary and physiologically realistic lab-grown human organs.

Vivodyne Appoints Julie O'Shaughnessy as Chief Operating Officer

05/08/2024

Clearsense has achieved a significant milestone in its commitment to healthcare data excellence by earning the Validated Data Stream designation from the National Committee for Quality Assurance (NCQA) Data Aggregator Validation Program. The NCQA's rigorous evaluation process ensures the quality and integrity of data from ingestion to end-user transition, providing assurance that their data streams meet the highest standards.

With this designation, the 1Clearsense Platform can now ingest clinical data from provider EMRs in real time, streamlining the process for standard supplemental data use in Healthcare Effectiveness Data and Information Set (HEDIS®) reporting and other quality programs.

/PRNewswire/ -- Clearsense®, a PaaS company that partners with healthcare organizations to increase data value, governance, and transparency, today announced...

04/17/2024

Exciting news from Foldax Inc.! Their TRIA valves have surpassed a cumulative 200 patient life years in 160+ active human recipients, showcasing the endurance of their heart valves. Their proprietary polymer resists calcification and improves blood flow, thus increasing the durability of their heart valves. TRIA valves are set to revolutionize heart valve disease management, offering patients improved quality of life without the need for long-term use of anticoagulants.

TRIA polymer surgical heart valves from Foldax surpass 200 patient life years, demonstrating durable positive results.

04/04/2024

Linnaeus Therapeutics, Inc. has just been granted a European composition of matter patent for their lead cancer therapeutic compound, LNS8801. With a US patent already issued, this additional patent will provide critical market protection for LNS8801 into the 2040s.

Linnaeus is currently conducting a phase 1/2 study assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced cancer, and are already seeing encouraging results. Stay tuned for updates on their groundbreaking work!

/PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and...

03/26/2024

Sienza Energy, a Caltech-incubated battery company backed by Kairos Ventures, announced groundbreaking capacity test results for their 3D pure silicon anode. The test results showed that Sienza's batteries can store 2,941 milliampere-hours (mAh) of electricity for every gram of silicon, significantly higher than the industry standard for graphite, with a gravimetric capacity of only 372 mAh per gram!

/PRNewswire/ -- Sienza Energy, a Caltech-incubated battery company backed by Los Angeles-based philanthropist Dr. Patrick Soon-Shiong and Kairos ventures...

03/21/2024

Amorphology, Inc. & Liquidmetal Technologies advanced their partnership by entering into a manufacturing license agreement. This agreement aims to leverage Amorphology's deep materials science expertise and precision manufacturing capabilities of amorphous metals here in the US to meet growing industry demands.

LAKE FOREST, Calif., March 19, 2024--Liquidmetal® Technologies, Inc. (OTCQB: LQMT), On March 15, 2024, Liquidmetal Technologies Inc. (the "Company") entered into an Amended License Agreement to expand its existing agreement with Amorphology, Inc., a developer and producer of specialized BMG applica...